- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA clears Park’s MCAT system
Park Medical Systems of Lachine, Quebec, has received the Foodand Drug Administration's go-ahead to market its Molecular CodedAperture Technology (MCAT), a collimator-based method for improvinggamma camera imaging at all energy levels.MCAT consists of
Park Medical Systems of Lachine, Quebec, has received the Foodand Drug Administration's go-ahead to market its Molecular CodedAperture Technology (MCAT), a collimator-based method for improvinggamma camera imaging at all energy levels.
MCAT consists of macro-collimators that attach to standard detectors,creating a coded pattern that is detected by the camera's photomultipliertube array. Software decodes the pattern into a high-resolutionimage covering a wide range of energies. Park believes the techniqueis more versatile than coincidence-detection methods for oncologyimaging.
Park will show the MCAT module, as well as clinical images, atthe Society of Nuclear Medicine meeting in San Antonio, TX, inJune.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
